Literature DB >> 26446982

In Brief: Endothelial-to-mesenchymal transition.

Gonzalo Sanchez-Duffhues1, Valeria Orlova2, Peter Ten Dijke1.   

Abstract

Recent evidence has highlighted the role of endothelial-to-mesenchymal transition (EndoMT) in the onset and progression of a number of human pathologies. EndoMT involves the loss of an endothelial signature to generate unspecialized mesenchymal-like cells, susceptible to being re-differentiated into mesodermal cell types, including osteoblasts, chondrocytes, and adipocytes. Therefore, modulation of the molecular pathways controlling EndoMT can be considered as a therapeutic approach for particular human diseases. In addition, EndoMT may be harnessed for tissue engineering by producing multipotent mesenchymal cells able to differentiate into mutiple cell types.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  EndoMT; TGF-β; endothelial cell; β-catenin

Mesh:

Substances:

Year:  2016        PMID: 26446982     DOI: 10.1002/path.4653

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  22 in total

1.  A Metabolic Basis for Endothelial-to-Mesenchymal Transition.

Authors:  Jianhua Xiong; Hiroyuki Kawagishi; Ye Yan; Jie Liu; Quinn S Wells; Lia R Edmunds; Maria M Fergusson; Zu-Xi Yu; Ilsa I Rovira; Evan L Brittain; Michael J Wolfgang; Michael J Jurczak; Joshua P Fessel; Toren Finkel
Journal:  Mol Cell       Date:  2018-02-08       Impact factor: 17.970

Review 2.  Fine-tuning vascular fate during endothelial-mesenchymal transition.

Authors:  Lin Xiao; Andrew C Dudley
Journal:  J Pathol       Date:  2016-11-10       Impact factor: 7.996

Review 3.  Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Physiol Rev       Date:  2019-04-01       Impact factor: 37.312

Review 4.  The Provenance, Providence, and Position of Endothelial Cells in Injured Spinal Cord Vascular Pathology.

Authors:  Manjeet Chopra; Ankita Bhagwani; Hemant Kumar
Journal:  Cell Mol Neurobiol       Date:  2022-08-09       Impact factor: 4.231

5.  Epigallocatechin-3-Gallate (EGCG) Mitigates Endothelial and Circulating Cells Alterations Following PLLA Electrospun Mat Placement.

Authors:  Carmen Ciavarella; Ilenia Motta; Santino Blando; Sabrina Valente; Fulvia Farabegoli; Maria Letizia Focarete; Mauro Gargiulo; Gianandrea Pasquinelli
Journal:  Biomedicines       Date:  2022-05-30

6.  Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation.

Authors:  Craig B Woda; Sarah Bruneau; Anne Linde Mak; Zdenka Haskova; Kaifeng Liu; Chandra C Ghosh; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2019-09-18       Impact factor: 3.575

7.  Diffuse Large B-Cell Lymphoma Promotes Endothelial-to-Mesenchymal Transition via WNT10A/Beta-Catenin/Snail Signaling.

Authors:  Xianting Sun; Jianchen Fang; Fen Ye; Shuxian Zhang; Honghui Huang; Jian Hou; Ting Wang
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

8.  Embryonic Stem Cell-like Population in Dupuytren's Disease.

Authors:  Sabrina P Koh; Nicholas On; Helen D Brasch; Alice M Chibnall; James R Armstrong; Paul F Davis; Swee T Tan; Tinte Itinteang
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-11-23

Review 9.  Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases.

Authors:  Sonsoles Piera-Velazquez; Fabian A Mendoza; Sergio A Jimenez
Journal:  J Clin Med       Date:  2016-04-11       Impact factor: 4.241

10.  TGF-β1-mediated exosomal lnc-MMP2-2 increases blood-brain barrier permeability via the miRNA-1207-5p/EPB41L5 axis to promote non-small cell lung cancer brain metastasis.

Authors:  Dongming Wu; Shihua Deng; Li Li; Teng Liu; Ting Zhang; Jing Li; Ye Yu; Ying Xu
Journal:  Cell Death Dis       Date:  2021-07-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.